Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of a modified virus called
VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis
virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta),
which may protect normal healthy cells from becoming infected with the virus, and TYRP1,
which is expressed mainly in melanocytes (specialized skin cell that produces the protective
skin-darkening pigment melanin) and melanoma tumor cells, and may trigger a strong immune
response to kill the melanoma tumor cells.